サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：血液・血漿成分市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年
市場調査レポート
商品コード
1321035

血液・血漿成分市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年

Blood & Plasma Components Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Products, By Application, By End User, By company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 117 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

血液・血漿成分市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 117 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の血液・血漿成分市場は、2023年から2027年の予測期間中に目覚ましい成長を遂げると予測されています。

主な要因としては、手術件数の増加、外傷や交通事故の急増、がんを含む慢性疾患患者の増加が市場の成長を抑制しています。血液は生命を維持するための体液であり、全身を流れ、体組織に栄養、電解質、ホルモン、抗体、ビタミンを供給します。血漿は血液の一部で水性であり、塩分とタンパク質を含み、その中に血小板、白血球、赤血球が浮遊しています。市場の成長を支えるその他の要因としては、献血の意義に関連する意識の高まり、患者数の多さ、政府の取り組み、研究開発活動への投資の増加、様々な血液団体が実施する献血キャンペーン、高齢者人口の増加、研究開発活動の増加、技術の進歩などが挙げられます。また、市場企業が実施するパートナーシップや製品発売などの戦略的イニシアチブは、市場の成長を増強しています。

外傷と交通事故の増加

外傷や交通事故の発生率の増加は、市場の成長を促進する重要な要因です。時として、人々は出血などの外傷に見舞われ、存在する血液の量が減少し、身体によって十分に速く補充されなくなります。レビューによると、2018年には毎年約6万人のアメリカ人が出血や失血で死亡しています。また、交通事故の増加により、体内の血液が過剰に失われ、出血を防ぐために血液や血漿を輸血する需要が高まっています。このような状況が、血液・血漿成分市場の世界の成長を増大させています。WHOの調査によると、2020年には世界中で毎年150万人近くが交通事故が原因で死亡しています。

血液疾患と手術の頻度の増加

出血性疾患の増加や世界の手術件数の増加が市場の成長を後押ししています。血友病AおよびB、フォン・ヴィレブランド病は最も一般的な出血性疾患です。例えば、2019年には世界中で195,263人が血友病と診断され、80,302人がフォン・ヴィレブランド病と診断されました。これらに加えて、手術中に多くの血液が失われ、輸血が必要になる可能性が高まるため、手術症例の増加が市場の成長を促しています。また、貧血患者では輸血の需要が高まる。例えば、世界では毎年約3億1,000万件の大手術が行われており、そのうち5,000万件は米国で、2,000万件は欧州で行われています。

無機的成長戦略の採用増加

合併、提携、買収、パートナーシップなど、さまざまな無機的成長戦略が市場の成長を支えています。例えば、Blood Center of WisconsinはSysLogic Inc.と提携し、血液製剤の収集や輸血中にRFID技術をどのように活用して患者の安全性を高められるかを調査しました。同様に、2018年には、Invitrx Inc.が、神経新生と認知機能を高める抗老化効果が期待できる可塑性促進タンパク質を含む臍帯血漿製品を発売しました。

市場セグメンテーション

世界の血液・血漿成分市場は、製品、用途、エンドユーザー、企業に区分されます。製品に基づくと、市場は充填赤血球、血小板製品、凍結血漿、血漿由来製品に分けられます。血漿由来製品に基づくと、市場はさらに免疫グロブリン、アルブミン、凝固因子濃縮物、その他に分けられます。用途別では、市場は血液学、固形腫瘍管理、その他に分けられます。血液学に基づくと、市場はさらにヘモグロビン血症、血液悪性腫瘍治療、凝固異常症、その他に分けられます。エンドユーザー別では、市場は病院、診断研究所、その他に分けられます。国別では、米国は慢性疾患や手術件数が増加しているため、予測期間中に有利な市場になると予想されます。

市場プレイヤー

CSL Limited、Grifols S.A.、ADMA Biologics, Inc.、武田薬品工業株式会社、Octapharma AG、Kedrion S.p.A.、Emergent BioSolutions Inc.、Bio Products Laboratory Ltd.、LFB S.A.、Versiti, Inc.などが、この市場で事業を展開している大手企業です。

利用可能なカスタマイズ

TechSciリサーチは、与えられた市場データを用いて、企業の特定のニーズに応じたカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の血液・血漿成分市場に与える影響

第5章 顧客の声

第6章 血液・血漿成分の世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 用途別
    • エンドユーザー別
    • 企業別
    • 地域別
  • 市場マップ

第7章 北米の血液・血漿成分市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 用途別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州の血液・血漿成分市場の展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 用途別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋の血液・血漿成分市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 用途別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米の血液・血漿成分市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 用途別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの血液・血漿成分市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 用途別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

第14章 競合情勢

  • CSL Limited
  • Grifols S.A.
  • ADMA Biologics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A
  • Emergent BioSolutions Inc.
  • Bio Products Laboratory Ltd.
  • LFB S.A.
  • Versiti, Inc.

第15章 戦略的提言

目次
Product Code: 12989

The global blood & plasma components market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include the growing volume of surgeries, the surge in the prevalence of trauma and road accidents, and the increase in the number of people from chronic conditions, including cancer are curbing the growth of the market. Blood is a life-sustaining fluid that flows throughout the body, giving nourishment, electrolytes, hormones, antibodies, and vitamins to body tissues. Plasma is a part of the blood which is aqueous in nature; it contains salt and proteins in which platelets, white blood cells, and red blood cells are suspended. The other factors supporting the market's growth are, rising awareness associated with the significance of blood donations, high patient pool, government initiatives, increasing investments for research and development activities, several blood donation campaigns undertaken by various blood organizations, rise in the elderly population base, rise in R&D activities, and technological advancements. Also, the strategic initiatives such as partnerships and product launches undertaken by the market players are augmenting the growth of the market.

Increasing Occurrence of Trauma and Road Accidents

The growing incidence of trauma and road accidents is a significant factor propelling the growth of the market. At times, people suffer from traumas such as hemorrhage; the amount of blood present gets reduced and cannot be replaced fast enough by the body. According to a review, in 2018, approximately 60,000 Americans died from hemorrhaging or blood loss every year. Also, owing to the rise in the number of road accidents, excessive blood loss from the body is raising the demand for blood or plasma transfusion to prevent bleeding. Thus, in turn, these situations are augmenting the growth of the blood and plasma component market globally. According to WHO research, in 2020, nearly 1.5 million people died every year due to road traffic injuries around the globe.

Rising Frequency of Blood Diseases and Surgeries

The growing incidences of bleeding disorders and the rising number of surgeries across the globe are bolstering the growth of the market. Hemophilia A and B and von Willebrand disease are the most common bleeding disorders. For instance, in 2019, 195,263 people globally were diagnosed with hemophilia, and 80,302 were diagnosed with von Willebrand disease. In addition to these, increasing cases of surgeries are impelling the growth of the market as a lot of blood is lost during the operations, which increases the chances of needing transfusions. Also, the demand for blood transfusion rises in patients who are anemic. For instance, approximately 310 million major surgeries are performed every year globally, of which 50 million are in the USA, and 20 million are in Europe.

Increasing Adoption of Inorganic Growth Strategies

Various inorganic growth strategies such as mergers, collaborations, acquisitions, and partnerships are supporting the growth of the market. For instance, the Blood Center of Wisconsin collaborated with SysLogic Inc. to research how RFID technology can be utilized to heighten the safety of the patient while collecting and transfusing blood products. Similarly, in 2018, Invitrx Inc. launched a cord blood plasma product that contains plasticity-promoting proteins that may have anti-aging effects that increase neurogenesis and cognitive function.

Market Segmentation

The global blood & plasma components market is segmented into products, applications, end user, and company. Based on products, the market is divided into packed red blood cells, platelets products, frozen plasma, and plasma-derived products. Based on plasma-derived products, the market is further divided into immunoglobulins, albumins, coagulation factor concentrates, and others. Based on application, the market is divided into hematology, solid tumor management, and others. Based on hematology, the market is further divided into hemoglobinopathy, hematologic malignancies treatment, coagulopathy, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of chronic diseases and surgeries in the country.

Market Players

CSL Limited, Grifols S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., and Versiti, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global blood & plasma components market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Blood & Plasma Components Market, By Products:

  • Packed Red Blood Cells
  • Platelets Products
  • Frozen Plasma
  • Plasma Derived Products
    • Immunoglobulins
    • Albumins
    • Coagulation Factor Concentrates
    • Others
    • Blood & Plasma Components Market, By Application:
  • Hematology
    • Hemoglobinopathy
    • Hematologic Malignancies Treatment
    • Coagulopathy
    • Others
  • Solid Tumor Management
  • Others

Blood & Plasma Components Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Blood & Plasma Components Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Blood & Plasma Components Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Blood & Plasma Components Market

5. Voice of Customer

6. Global Blood & Plasma Components Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 6.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 6.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 6.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 6.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 6.2.4. By Company (2021)
    • 6.2.5. By Region
  • 6.3. Market Map

7. North America Blood & Plasma Components Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 7.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 7.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 7.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 7.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Blood & Plasma Components Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Products
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Blood & Plasma Components Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Products
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Blood & Plasma Components Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Products
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User

8. Europe Blood & Plasma Components Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 8.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 8.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 8.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 8.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Blood & Plasma Components Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Products
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Blood & Plasma Components Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Products
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Blood & Plasma Components Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Products
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Blood & Plasma Components Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Products
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Blood & Plasma Components Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Products
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Asia-Pacific Blood & Plasma Components Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 9.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 9.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 9.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 9.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Blood & Plasma Components Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Products
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. India Blood & Plasma Components Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Products
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Blood & Plasma Components Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Products
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Blood & Plasma Components Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Products
        • 9.3.4.2.2. By Application
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Blood & Plasma Components Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Products
        • 9.3.5.2.2. By Application
        • 9.3.5.2.3. By End User

10. South America Blood & Plasma Components Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 10.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 10.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 10.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 10.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Blood & Plasma Components Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Products
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Blood & Plasma Components Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Products
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Blood & Plasma Components Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Products
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Middle East and Africa Blood & Plasma Components Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Products (Packed Red Blood Cells, Platelets Products, Frozen Plasma, Plasma Derived Products)
      • 11.2.1.1. By Plasma Derived Products (Immunoglobulins, Albumins, Coagulation Factor Concentrates, Others)
    • 11.2.2. By Application (Hematology, Solid Tumor Management, Others)
      • 11.2.2.1. By Hematology (Hemoglobinopathy, Hematologic Malignancies Treatment, Coagulopathy, Others)
    • 11.2.3. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Blood & Plasma Components Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Products
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Blood & Plasma Components Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Products
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Blood & Plasma Components Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Products
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. CSL Limited
  • 14.2. Grifols S.A.
  • 14.3. ADMA Biologics, Inc.
  • 14.4. Takeda Pharmaceutical Company Limited
  • 14.5. Octapharma AG
  • 14.6. Kedrion S.p.A
  • 14.7. Emergent BioSolutions Inc.
  • 14.8. Bio Products Laboratory Ltd.
  • 14.9. LFB S.A.
  • 14.10. Versiti, Inc.

15. Strategic Recommendations